Fueled Framework / GLP-1 Optimization / 6 Week Ozempic Plan GLP-1 Optimization 6 Week Ozempic Weight Loss Plan: What to Expect Week by Week and How to Maximise Results Most people lose 5 to 10 pounds in the first six weeks on Ozempic. But the first four weeks are the starter dose — not therapeutic … Read more
Fueled Framework / GLP-1 Optimization / Microdosing Ozempic GLP-1 Optimization Microdosing Ozempic: What It Actually Is, Why People Do It, and What the Evidence Shows Thousands of people are taking Ozempic and Wegovy at doses far below the standard therapeutic range. Some are doing it safely for legitimate reasons. Others are taking on risks they … Read more
Ozempic teeth describes a cluster of dental and oral health changes — dry mouth, enamel erosion, accelerated cavities, gum inflammation — reported by an increasing number of dentists seeing GLP-1 patients. The medication does not chemically damage teeth directly. Four indirect mechanisms do: GLP-1 receptor activation suppressing salivary gland function, dehydration from suppressed thirst compounding dry mouth, stomach acid from reflux and vomiting eroding enamel, and nutritional deficiencies from reduced food intake depleting the minerals teeth need. Unlike most GLP-1 side effects, dental damage from enamel erosion is not reversible when the medication stops. This article covers all four mechanisms, the seven-point oral protection protocol, and the one thing most people do wrong after vomiting that actively accelerates enamel damage.
Ozempic butt describes the loss of gluteal volume, shape, and firmness experienced during rapid weight loss on GLP-1 medications. The medication does not target gluteal tissue — two mechanisms drive it simultaneously. First, the gluteal region contains peripheral subcutaneous fat that is often mobilised before deeper visceral fat during calorie restriction. Second, without deliberate protein targeting and resistance training, 25 to 40% of weight lost comes from lean mass including the gluteal muscles themselves. The fat component is difficult to reverse selectively. The muscle component is highly reversible within 8 to 12 weeks of consistent resistance training. This article covers both causes, a six-exercise gluteal protocol, the protein targets that support it, and an honest table of what is and is not recoverable without cosmetic intervention.
Ozempic vulva is one of the most searched and least discussed side effects of GLP-1 medications. Vaginal dryness, skin laxity around the vulva, pelvic floor weakness, and changes in vaginal discharge are being reported by thousands of women on Ozempic, Wegovy, Mounjaro, and Zepbound — and most were never told it could happen. The medication itself does not directly cause these changes. They are driven by four consequences of rapid weight loss: oestrogen reduction as fat tissue decreases, chronic dehydration from suppressed thirst signals, reduced dietary fat lowering hormone production, and structural fat loss from the vulvar area. This article covers the mechanism behind each cause and seven evidence-based interventions from omega-3s and hydration to pelvic floor physiotherapy and topical oestrogen.
Most people treat every day of their GLP-1 injection week the same. That is the mistake. Semaglutide peaks 24 hours after injection. Tirzepatide builds to peak at 48 to 72 hours. The nausea, appetite suppression, and food tolerance all follow that curve — and what you eat should be structured around it. This free personalised tool takes your injection day, time, medication, and dose and gives you a 72-hour eating guide covering the pre-injection window, the peak nausea day, the recovery phase, and the optimal high-appetite days. Plus a specific guide on what to eat the day after your Ozempic or Mounjaro injection — the hardest eating day of the week for most users.
Menopause creates a perfect metabolic storm for weight gain — and most of it has nothing to do with willpower or eating more. Oestrogen decline shifts fat storage from the hips and thighs to the visceral abdomen. Muscle loss accelerates from 3 to 5% per decade to up to 8% after menopause. Insulin resistance worsens as oestrogen’s insulin-sensitising effects are withdrawn. Sleep disruption from hot flushes elevates ghrelin and cortisol nightly. And appetite regulation in the hypothalamus loses the oestrogenic support it was depending on. GLP-1 medications address each of these mechanisms directly — improved insulin sensitivity, visceral fat reduction, and hypothalamic appetite regulation that partially restores what oestrogen was providing. But the muscle and bone loss risks are more pronounced in menopausal women than in the general GLP-1 population, and the nutritional strategy needs to account for that from day one. This article covers the full metabolic picture, how Ozempic, Wegovy, Mounjaro, and Zepbound interact with the hormonal changes of menopause, whether GLP-1 and HRT can be combined, and the specific nutrition protocol for menopausal women on GLP-1 therapy.
Fatty liver disease (MASLD) affects 80% of people with obesity, which means the majority of GLP-1 medication users have some degree of it without any symptoms or awareness. A landmark 2023 randomised controlled trial published in the New England Journal of Medicine found semaglutide resolved MASH — the inflammatory form of fatty liver — in 62.9% of participants versus 34.3% on placebo, using liver biopsy as the primary endpoint. This article covers what fatty liver disease actually is, the four disease stages, the three mechanisms by which GLP-1 medications reduce liver fat, the full trial data, the dietary strategies that accelerate the medication’s liver benefits, and what to ask your GP to monitor.
Most people regain significant weight after stopping Ozempic, Wegovy, Mounjaro, or Zepbound. The STEP 1 trial extension found two thirds of lost weight returns within a year of stopping semaglutide. The STEP 4 withdrawal trial showed 50% regain within 48 weeks. This is not a failure of willpower — it is a documented biological response involving hunger hormone rebound and metabolic adaptation. This article covers why it happens, the three paths available at goal weight, the nutrition strategy for the maintenance phase, and what the real-world data shows about who successfully maintains results after stopping.
A new risk prediction tool called Obscore — built from 200,000 people and published in Nature Medicine — has identified who will develop serious obesity complications before their BMI classifies them as obese. The research confirms what metabolic medicine has argued for years: BMI is a single number that measures one thing, and that one thing is not metabolic risk. This article covers what Obscore actually found, why the current BMI thresholds for Ozempic, Wegovy, Mounjaro, and Zepbound are inadequate, and what the markers that genuinely predict disease risk look like — and why the nutrition strategy for protecting muscle and metabolic health remains the same regardless of where you sit on the BMI scale.